Anti-GPRC5D CAR-T Therapy Elicits Responses After Anti-BCMA CAR Failure
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
Anti-GPRC5D CAR T-cell therapy can produce responses in patients with relapsed or refractory multiple myeloma, a phase 2 trial suggests.
A study sought to determine the effect of an antimicrobial stewardship team on carbapenem therapy in patients with hematologic disorders.
A review of myelofibrosis, including an update on treatment options, was presented at the 2023 ONA Summit.
A review of MDS/MDN, including new WHO guidelines and collaborative strategies for managing the care of patients with lower-risk MDS.
The unique needs of patients with AML undergoing maintenance therapy, including care disparities and challenges, are discussed at the 2023 ONA Summit.
Researchers sought to determine whether OS rates with CAR-T therapy were linked to household poverty and neighborhood opportunity for patients with ALL.
High-risk cytogenetics and extramedullary disease may be associated with worse survival outcomes of CAR T-cell therapy in relapsed or refractory multiple myeloma, a meta-analysis suggests.
Researchers outlined risks, mechanisms, and possible strategies related to cardiovascular toxicity with proteasome inhibitors for multiple myeloma therapy.
Sexual dysfunction may be common in cancer patients and survivors, but their sexual health is often overlooked.
What are some of the most important factors affecting outcomes in patients with multiple myeloma?